Zydus Cadila gets USFDA’s nod for Valsartan and Hydrochlorothiazide Tablets

16 Mar 2019 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Valsartan and Hydrochlorothiazide Tablets USP (US RLD -- Diovan HCT Tablets) in the strengths of 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg.

The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. 

The group now has 256 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

948.20 -2.75 (-0.29%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.